PHARMACEUTICAL COMPOSITION USED FOR PREVENTION AND/OR TREATMENT OF DISEASE DEVELOPED AND/OR ADVANCED BY DECREASE OR DEFICIENCY IN ACTIVITY OF BLOOD COAGULATION FACTOR VIII AND/OR ACTIVATED BLOOD COAGULATION FACTOR VIII
To provide pharmaceutical compositions for more effectively preventing and/or treating diseases that develop and/or advance due to a decrease or deficiency in the activity of blood coagulation factor VIII and/or activated blood coagulation factor VIII.SOLUTION: A pharmaceutical composition comprising a bispecific antigen-binding molecule that recognizes a blood coagulation factor IX and/or an activated blood coagulation factor IX and a blood coagulation factor X and/or an activated blood coagulation factor X is administered. The antigen binding molecule is administered as an initial dose of about 0.001 to 100 mg/kg, and is continuously administered multiple times at a continuous dose approximately the same as or less than the initial dose, and the interval between each administration is at least one day or more.SELECTED DRAWING: Figure 1【課題】血液凝固第VIII因子および/または活性化血液凝固第VIII因子の活性の低下ないし欠損によって発症および/または進展する疾患を、より効果的に予防および/または治療する医薬組成物の提供。【解決手段】血液凝固第IX因子および／または活性化血液凝固第IX因子ならびに血液凝固第X因子および/または活性化血液凝固第X因子を認識する二重特異性抗原結合分子を含む医薬組成物を投与する。該抗原結合分子は、約0.001～100mg/kgの初回用量として投与され、初回用量とほぼ同じ又はそれ未満の継続用量で複数回継続投与され、各投与の間隔が少なくとも1日以上であることを特徴とする。【選択図】図１
